Previous PostVenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
Next PostVenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio